Contact | 
Print version | 
PDF version | 
Send article | 
RSS-Feed
Oxford Genome Sciences announces new Therapeutic Antibody Deal with Medarex
New agreement to drive the development of OGeS' own pipeline of antibodies in cancer
20 Sep 2007 -
Oxford Genome Sciences (UK) Ltd (OGeS) announced a second partnering agreement with Medarex, Inc. This new agreement provides OGeS with broad access to Medarex's fully human antibody technology and will potentially enable OGeS to accelerate the development of its own pipeline of novel fully human antibodies in the field of cancer.
Under the terms of the agreement, OGeS will license Medarex's proprietary transgenic mouse technology to generate antibody therapeutics against cancer targets that OGeS identifies using its unique OGAP® database. OGeS will retain full worldwide rights to the new human antibodies generated, and Medarex has the right to receive license fees, milestone payments and royalties on commercial sales of any products that may result from this agreement. Further financial details were not disclosed.
Medarex's technology offers the potential for drug developers to generate high affinity fully human antibodies. OGeS will be able to potentially build a valuable and broad therapeutic antibodies pipeline by combining Medarex's technology with its OGAP database, which enables the identification of best in class targets,
In parallel, to further accelerate its pipeline development, OGeS has established a three-way agreement with Biosite Incorporated and Medarex. Medarex will provide access to its transgenic technology to Biosite, and Biosite will carry out the early stage antibody generation on behalf of OGeS for a potentially large number of OGeS' antibody programs. This is partly in exchange for Biosite receiving access to the OGeS diagnostic targets in colorectal and ovarian cancer. This arrangement is expected to improve OGeS' productivity to put top quality antibody therapeutic programs into development more quickly.
In addition, under a separate agreement between OGeS and Biosite, Biosite can also establish a companion diagnostic assay on certain programs selected by Biosite and OGeS. This provides OGeS with the opportunity to create a significant portfolio of personalised cancer therapeutics with companion diagnostics for many of its oncology targets.
Top
